The Rowan Centers Cody Baird Receives State of Connecticut General Assembly Citation for Volunteer Excellence
ASMB Stock | USD 11.95 0.28 2.29% |
About 62% of Assembly Biosciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Assembly Biosciences suggests that many traders are alarmed. The current market sentiment, together with Assembly Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Assembly Biosciences stock news signals to limit their universe of possible portfolio assets.
Assembly |
The Rowan Centers Cody Baird Receives State of Connecticut General Assembly Citation for Volunteer Excellence
Read at kalkinemedia.com
![]() |
Assembly Biosciences Fundamental Analysis
We analyze Assembly Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Assembly Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Assembly Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Assembly Biosciences is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Assembly Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Assembly Biosciences stock to make a market-neutral strategy. Peer analysis of Assembly Biosciences could also be used in its relative valuation, which is a method of valuing Assembly Biosciences by comparing valuation metrics with similar companies.
Peers
Assembly Biosciences Related Equities
NXTC | NextCure | 1.37 | ||||
ACHL | Achilles Therapeutics | 0.72 | ||||
SPRO | Spero Therapeutics | 1.28 | ||||
TIL | Instil Bio | 4.27 | ||||
CTMX | CytomX Therapeutics | 4.41 | ||||
NUVB | Nuvation Bio | 7.61 |
Complementary Tools for Assembly Stock analysis
When running Assembly Biosciences' price analysis, check to measure Assembly Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assembly Biosciences is operating at the current time. Most of Assembly Biosciences' value examination focuses on studying past and present price action to predict the probability of Assembly Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assembly Biosciences' price. Additionally, you may evaluate how the addition of Assembly Biosciences to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |